Belatacept utilization recommendations: an expert position

Josep M Grinyó, Klemens Budde, Franco Citterio, Bernard Charpentier

Research output: Contribution to journalArticle

10 Citations (Scopus)


There is a continuing need for an immunosuppressive therapy that offers a high benefit-risk profile for renal transplant recipients, supporting long-term patient and graft survival while minimizing cumulative nephrotoxicity and other side effects. Belatacept , the first biological agent developed for primary maintenance immunosuppression, was recently approved for use in Europe. Belatacept combined with corticosteroids and a mycophenolic acid is indicated for prophylaxis of graft rejection in adults receiving renal transplant. Its use is contraindicated in Epstein-Barr virus seronegative or serostatus unknown patients due to increased risk of developing posttransplant lymphoproliferative disorder.
Original languageEnglish
Pages (from-to)111-122
Number of pages12
JournalExpert Opinion on Drug Safety
Publication statusPublished - 2013


  • Graft Rejection
  • Graft Survival
  • Humans
  • Immunoconjugates
  • Immunosuppressive Agents
  • Kidney Transplantation
  • Patient Selection
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome


Dive into the research topics of 'Belatacept utilization recommendations: an expert position'. Together they form a unique fingerprint.

Cite this